Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

VYNE
VYNE Therapeutics Inc. Common Stock
stock NASDAQ

Market Open
Dec 18, 2025 12:54:35 PM EST
0.5800USD-2.950%(-0.0200)7,921,066
0.5800Bid   0.5800Ask   0.0000Spread
Pre-market
Dec 18, 2025 9:28:30 AM EST
0.6068USD+1.133%(+0.0068)637,439
After-hours
Dec 17, 2025 4:58:30 PM EST
0.5830USD-4.925%(-0.0300)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
08:04AM EST  VYNE Therapeutics Announces Phase 1b Data For FMX114 from Phase 1b/2a Trial For Treatment Of Mild-To-Moderate Atopic Dermatitis   Benzinga
08:00AM EST  Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents   GlobeNewswire Inc
Jan 13, 2022
11:45AM EST  VYNE Therapeutics Divests Topical Minocycline Assets; Transaction Includes Cash Payments Of $25M And Potential Milestones Of Up To $450M   Benzinga
07:00AM EST  Transaction includes cash payments of $25 million and potential milestones of up to $450 million   GlobeNewswire Inc
Jan 3, 2022
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that management will participate in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.   GlobeNewswire Inc
Dec 6, 2021
06:31AM EST  HC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7   Benzinga
Nov 18, 2021
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 11, 2021
11:55AM EST  VYNE Therapeutics's Return On Capital Employed Insights   Benzinga
Nov 10, 2021
07:53AM EST  VYNE Therapeutics Q3 EPS $(0.36) Misses $(0.32) Estimate, Sales $4.09M Miss $4.76M Estimate   Benzinga
07:51AM EST  VYNE Therapeutics Q3 Loss Per Share $0.41; Adj Loss Per Share $0.36   RTTNews
07:30AM EST  Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 4, 2021
09:09AM EDT  VYNE Therapeutics Announces BET Inhibitor, VYN201, Demonstrates Improvement In Reducing Fibrotic Tissue Mass And Overall Skin Repair Outcomes In Preclinical Study   Benzinga
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (BET) inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time.   GlobeNewswire Inc
Oct 28, 2021
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.   GlobeNewswire Inc
Oct 26, 2021
08:00AM EDT  -- VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroid -- VYN201 appeared well-tolerated in mice, as seen through animal body weight and skin condition -- VYN201 also demonstrates stronger inhibition of key Th17 cytokines in ex vivo data with human skin tissue when directly compared to JAK1/2 inhibitor, ruxolitinib   GlobeNewswire Inc
Oct 21, 2021
08:00AM EDT  Renowned Experts to Support VYNEs Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases   GlobeNewswire Inc
Oct 19, 2021
08:13AM EDT  VYNE Therapeutics Enrolls First Patient In Clinical Trial Of FMX114 For Mild-to-Moderate Atopic Dermatitis   RTTNews
08:02AM EDT  VYNE Therapeutics Enrolls First Patient In Clinical Trial Of FMX114 For Treatment Of Mild-To-Moderate Atopic Dermatitis   Benzinga
08:00AM EDT  Important milestone achieved as part of the Companys new corporate strategy to develop treatments for immuno-inflammatory diseases   GlobeNewswire Inc
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:24AM EDT  VYNE Therapeutics Announces Its China Partner's Enrollment Of First Patient In Phase 3 Study Of AMZEEQ In Patients With Moderate To Severe Acne   Benzinga
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ (minocycline) topical foam, 4% in moderate to severe acne. The study is being conducted by the Companys partner, Cutia Therapeutics (Cutia), for the purposes of seeking regulatory approval for AMZEEQ in China.   GlobeNewswire Inc
Oct 1, 2021
11:14AM EDT  Looking Into VYNE Therapeutics's Return On Capital Employed   Benzinga
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 27, 2021
10:20AM EDT  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Sep 20, 2021
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27th 30th.   GlobeNewswire Inc
Sep 13, 2021
10:27AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Sep 8, 2021
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th - 15th.   GlobeNewswire Inc
Aug 31, 2021
09:58AM EDT  Vyne Therapeutics Granted U.S. Patent Titled 'Wax foamable vehicle and pharmaceutical compositions thereof'   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
05:24PM EDT  Vyne Therapeutics Files Prospectus Supplement Related to Offering of Up to $50M in Shares of Common Stock   Benzinga
08:13AM EDT  VYNE Therapeutics Q2 Loss Per Share $0.39; Adj Loss Per Share $0.35   RTTNews
08:12AM EDT  Recap: VYNE Therapeutics Q2 Earnings   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
07:42AM EDT  VYNE Therapeutics Q2 EPS $(0.35), Inline   Benzinga
07:30AM EDT  Company announced license agreement with In4Derm Limited for BETi platform earlier this morning   GlobeNewswire Inc
07:18AM EDT  VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited   Benzinga
07:00AM EDT  VYNE Therapeutics Announces Licensing of BET Inhibitor Platform   GlobeNewswire Inc
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 2, 2021
08:46AM EDT  VYNE Therapeutics Announces Approval Of AMZEEQ And ZILXI In Chinese Economic Pilot Zone   RTTNews
08:10AM EDT  VYNE Therapeutics Reports Approval Of AMZEEG, ZILXI In Chinese Economic Pilot Zone   Benzinga
08:00AM EDT  VYNE Therapeutics Announces Approval of AMZEEQ   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 19, 2021
08:02AM EDT  VYNE Therapeutics Announces Initiation Of Investigator-Initiated Trial Evaluating AMZEEQ With Oral Isotretinoin In Patients With Moderate To Severe Acne   Benzinga
08:00AM EDT  VYNE Therapeutics Announces Initiation of Investigator Initiated   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 29, 2021
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021.   GlobeNewswire Inc
Jun 16, 2021
02:11PM EDT  Vyne Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'Efficacy and Safety of FMX114 Versus Vehicle in Adults With Atopic Dermatitis,' Shows Not Yet Recruiting   Benzinga
Jun 10, 2021
01:25PM EDT  VYNE Therapeutics Files For U.S. Patent Titled 'USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS'   Benzinga
Jun 8, 2021
03:34PM EDT  VYNE Therapeutics Granted Patent On Use Of NK-1 Receptor Antagonist Serlopitant In Pruritus   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
06:50AM EDT  HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $11   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:21AM EDT  VYNE Therapeutics Q1 Adj. EPS $(0.37) Beats $(0.41) Estimate, Sales $4.12M Miss $5.31M Estimate   Benzinga
07:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced financial results for the first quarter ended March31, 2021 and provided a corporate update.   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 28, 2021
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.   GlobeNewswire Inc
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 6, 2021
09:35AM EDT  VYNE Therapeutics Granted U.S. Patent Titled 'Surfactant-free, water-free formable composition and breakable foams and their uses'   Benzinga
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 16, 2021
04:42PM EDT  VYNE Therapeutics Director Patrick Lepore Discloses Purchase Of 12,500 Shares At Average Price Of $7.41   Benzinga
03:08PM EDT  USPTO Site Shows VYNE Therapeutics Patent For 'Surfactant-free water-free foamable compositions, breakable foams and gels and their uses'   Benzinga
Mar 4, 2021
04:01PM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.   GlobeNewswire Inc
07:10AM EST  VYNE Therapeutics Q4 EPS $(0.55) Misses $(0.53) Estimate, Sales $4.29M Miss $4.71M Estimate   Benzinga
07:09AM EST  VYNE Therapeutics Q4 EPS $(0.43) Beats $(0.53) Estimate, Sales $4.29M Miss $4.71M Estimate   Benzinga
07:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Mar 1, 2021
04:01PM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference.   GlobeNewswire Inc
08:08AM EST  VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis   Benzinga
08:00AM EST  VYNE Therapeutics Announces Development Program for FMX114   GlobeNewswire Inc
Feb 23, 2021
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, March 4, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.   GlobeNewswire Inc
Feb 11, 2021
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company)today announced that its Board of Directors has approved a reverse stock split of the Companys common stock at a ratio of 1-for-4. The reverse stock split was previously approved by stockholders at the Annual Meeting of Stockholders held on August 3, 2020.   GlobeNewswire Inc
Feb 6, 2021
01:27PM EST  Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More   Benzinga
Feb 2, 2021
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
Feb 1, 2021
08:13AM EST  VYNE Therapeutics Announces FDA Approval Of AMZEEQ Label Update   RTTNews
08:13AM EST  VYNE Therapeutics Announces FDA Approval of AMZEEQ (Minocycline) Label Update   Benzinga
08:00AM EST  VYNE Therapeutics Announces FDA Approval of AMZEEQ   GlobeNewswire Inc
Jan 29, 2021
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company)today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of $2.37 per share.   GlobeNewswire Inc
Jan 26, 2021
08:00AM EST  VYNE Therapeutics Announces $50M Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules   Benzinga
07:59AM EST  VYNE Therapeutics Announces $50 Million Registered Direct Offering   GlobeNewswire Inc
06:08AM EST  VYNE Therapeutics Sees Prelim. Q4 Sales $4M-$4.5M vs $5.18M Est.   Benzinga
Jan 25, 2021
09:44AM EST  ROCE Insights For VYNE Therapeutics   Benzinga
Jan 21, 2021
08:11AM EST  VYNE Therapeutics Announces Contract Execution For AMZEEQ And ZILXI With Major Pharmacy Benefit Management Company   Benzinga
08:00AM EST  VYNE Therapeutics Announces Contract Execution for   GlobeNewswire Inc
Jan 5, 2021
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event.   GlobeNewswire Inc
Dec 17, 2020
08:06AM EST  VYNE Therapeutics Reports Successful End-Of-Phase 2 Meeting With FDA For FCD105 In Acne   Benzinga
08:00AM EST  VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with   GlobeNewswire Inc
Dec 16, 2020
08:00AM EST  VYNE Therapeutics Added to Nasdaq Biotechnology Index   GlobeNewswire Inc
Dec 15, 2020
08:18AM EST  VYNE Announces New U.S. Patent Expiring In 2037 For AMZEEQ Topical Foam, 4%   RTTNews
08:02AM EST  VYNE Therapeutics Highlights New U.S. Patent Expiring in 2037 for AMZEEQ (minocycline) Topical Foam, 4%   Benzinga
08:00AM EST  VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for   GlobeNewswire Inc
Dec 1, 2020
08:09AM EST  VYNE Therapeutics Announces Publication Of Long-Term Safety & Efficacy Data For ZILXI Topical Foam, 1.5% In Journal Of Clinical And Aesthetic Dermatology   Benzinga
08:00AM EST  ZILXIis the First FDA Approved MinocyclineProduct for the Treatment ofInflammatory Lesions ofRosaceain AdultsZILXIdemonstrated a favorable safety and tolerability profile for up to 52 weeks of treatmentEfficacy of ZILXI continued to develop for an additional 40 weeks of treatment after an initial treatment period of 12 weeks   GlobeNewswire Inc
Nov 25, 2020
08:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.   GlobeNewswire Inc
Nov 5, 2020
07:25AM EST  VYNE Therapeutics Q3 Adj. EPS $(0.13) Beats $(0.17) Estimate   Benzinga
07:00AM EST  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced financial results for the third quarter ended September30, 2020 and provided a corporate update.   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Oct 28, 2020
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.   GlobeNewswire Inc
Oct 7, 2020
08:06AM EDT  VYNE Therapeutics Announces Express Scripts Has Elected To Cover ZILXI, Effect Oct. 2   Benzinga
08:02AM EDT  VYNE Therapeutics Announces Covered Status for ZILXI(tm) (minocycline) with   PR Newswire
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced a coverage update for its novel ZILXI(minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide.   GlobeNewswire Inc
Oct 5, 2020
06:14AM EDT  HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Raises Price Target to $3.5   Benzinga
Oct 1, 2020
07:30AM EDT  VYNE Announces ZILXI Topical Foam, 1.5% Available In Pharmacies Nationwide On October 1st   RTTNews
07:15AM EDT  VYNE Therapeutics Announces ZILXI Topical Foam, 1.5% Is Available In Pharmacies Nationwide Today, October 1st   Benzinga
07:02AM EDT  VYNE Therapeutics Announces ZILXI(tm) (minocycline) topical foam, 1.5%   PR Newswire
07:00AM EDT  ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults   GlobeNewswire Inc
Sep 23, 2020
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that the Company will host a physician symposium on AMZEEQ and ZILXI on Thursday, October 1, 2020 from 12pm 3pm ET.   GlobeNewswire Inc
Sep 14, 2020
08:22AM EDT  VYNE Therapeutics Adds Patrick LePore To Its Board   RTTNews
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.   GlobeNewswire Inc
Sep 9, 2020
08:00AM EDT  VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.   GlobeNewswire Inc
Sep 8, 2020
08:02PM EDT  CEO Domzalski Buys 75,000 Of VYNE Therapeutics @$1.38/Share   Benzinga
08:13AM EDT  Menlo Therapeutics Announces Completion Of Corporate Name Change To VYNE Therapeutics   RTTNews
08:02AM EDT  Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE   PR Newswire
08:00AM EDT  Menlo Therapeutics Announces Completion of Corporate Name Change   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC